MX2021011316A - Piridazinonas y metodos de uso de estas. - Google Patents

Piridazinonas y metodos de uso de estas.

Info

Publication number
MX2021011316A
MX2021011316A MX2021011316A MX2021011316A MX2021011316A MX 2021011316 A MX2021011316 A MX 2021011316A MX 2021011316 A MX2021011316 A MX 2021011316A MX 2021011316 A MX2021011316 A MX 2021011316A MX 2021011316 A MX2021011316 A MX 2021011316A
Authority
MX
Mexico
Prior art keywords
methods
pyridazinones
compounds
formula
disclosed
Prior art date
Application number
MX2021011316A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Jean-Christophe P Harmange
John Francis Reilly
Liron Walsh
Peter H Mundel
Amy Kieu Duyen Westerling-Bui
Gal Marie - Francoise Yveline Coeffet-Le
Michael Broxson
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MX2021011316A publication Critical patent/MX2021011316A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Se describen métodos terapéuticos, por ejemplo, para tratar enfermedades renales, usando compuestos de Fórmula (A) en combinación con un segundo agente terapéutico.
MX2021011316A 2019-03-20 2020-03-18 Piridazinonas y metodos de uso de estas. MX2021011316A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821178P 2019-03-20 2019-03-20
PCT/US2020/023369 WO2020191056A1 (en) 2019-03-20 2020-03-18 Pyridazinones and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2021011316A true MX2021011316A (es) 2021-10-13

Family

ID=72519163

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011316A MX2021011316A (es) 2019-03-20 2020-03-18 Piridazinonas y metodos de uso de estas.

Country Status (10)

Country Link
US (1) US20220152031A1 (es)
EP (1) EP3941475A4 (es)
CN (1) CN113939295A (es)
AU (1) AU2020240059A1 (es)
CA (1) CA3132580A1 (es)
IL (1) IL286481A (es)
MA (1) MA55381A (es)
MX (1) MX2021011316A (es)
SG (1) SG11202109568TA (es)
WO (1) WO2020191056A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852533B8 (en) * 2018-09-18 2024-07-17 Gfb (Abc), Llc Pyridazinones and methods of use thereof
KR20230028522A (ko) * 2020-07-03 2023-02-28 우한 엘엘 사이언스 앤드 테크놀로지 디벨롭먼트 컴퍼니, 리미티드 헤테로고리 화합물 및 이의 용도
JP2024533411A (ja) * 2021-09-10 2024-09-12 メッドシャイン ディスカバリー インコーポレイテッド ハロゲン置換のピリダジノン系化合物及びその使用
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
WO2024027752A1 (zh) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 包含杂环化合物的药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945857A (en) * 1955-05-06 1960-07-19 Monsanto Chemicals Pyridazinones
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2099743A1 (en) * 1992-07-02 1994-01-03 Akihiko Ishida Pyridazinone derivatives and processes for preparing the same
EP0737193A1 (en) * 1993-12-29 1996-10-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
US20050043315A1 (en) * 2002-01-02 2005-02-24 Hideo Tsutsumi Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
US20050165032A1 (en) * 2004-01-23 2005-07-28 Norman Mark H. Vanilloid receptor ligands and their use in treatments
WO2006044504A1 (en) * 2004-10-13 2006-04-27 Merck & Co., Inc. Cgrp receptor antagonists
CN101232885A (zh) * 2005-01-25 2008-07-30 神经能质公司 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物
RU2396269C2 (ru) * 2005-12-01 2010-08-10 Ф.Хоффманн-Ля Рош Аг Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpt1)
US20090227588A1 (en) * 2005-12-05 2009-09-10 Roman Wolfgang Fleck Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
WO2009114677A1 (en) * 2008-03-13 2009-09-17 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
WO2009117157A1 (en) * 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
EP2881390A1 (en) * 2013-12-04 2015-06-10 Sanofi Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
WO2019055966A2 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. PYRIDAZINONES AND METHODS OF USE

Also Published As

Publication number Publication date
CA3132580A1 (en) 2020-09-24
MA55381A (fr) 2022-01-26
JP2022525506A (ja) 2022-05-17
US20220152031A1 (en) 2022-05-19
AU2020240059A1 (en) 2021-10-28
CN113939295A (zh) 2022-01-14
WO2020191056A8 (en) 2021-09-30
WO2020191056A1 (en) 2020-09-24
EP3941475A1 (en) 2022-01-26
EP3941475A4 (en) 2023-01-25
IL286481A (en) 2021-12-01
SG11202109568TA (en) 2021-10-28

Similar Documents

Publication Publication Date Title
MX2021011316A (es) Piridazinonas y metodos de uso de estas.
WO2019055966A3 (en) PYRIDAZINONES AND METHODS OF USE
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12021550443A1 (en) Pyridazinones and methods of use thereof
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
MX2020009773A (es) Terapia de combinacion.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
EA201991622A1 (ru) Комплексная терапия для лечения рака
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2019003134A (es) Terapia de combinacion.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2024008461A (es) Metodos para tratar trastornos linfoproliferativos malignos.
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
MX2020001727A (es) Terapia de combinacion.
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2022000811A (es) Inhibidores de enzimas.
MX2021004366A (es) Tratamiento de enfermedades neurologicas con zilucoplan.
MX2021012418A (es) Compuestos heterociclicos y sus usos.
MX2022005358A (es) Composiciones de copolímero de bloque sensibles al ph, micelas, y métodos de uso.
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.